Publications by authors named "Laia Paré"

Are you Laia Paré?   Register this Author

Coamplification of protects -amplified breast cancers from targeted therapy.
Proc Natl Acad Sci U S A 2018 Mar 23;115(11):E2594-E2603. Epub 2018 Feb 23.
Department of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298;

GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.
Cell Rep 2017 Nov;21(8):2183-2197
Glioma and Neural Stem Cell Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors Team, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:


HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Lancet Oncol 2017 Apr 24;18(4):545-554. Epub 2017 Feb 24.
Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:





Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Int J Radiat Oncol Biol Phys 2011 Dec 11;81(5):1319-27. Epub 2011 May 11.
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
J Cancer Res Clin Oncol 2010 Nov 18;136(11):1681-9. Epub 2010 Feb 18.
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Pare Claret 167, 08025 Barcelona, Spain.




Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.
Bioinformatics 2016 04 24;32(7):1097-9. Epub 2015 Nov 24.
Bioinformatics and Computational Laboratory, Princess Margaret Cancer Centre, University Health Network and Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Eur Urol 2016 11 2;70(5):709-713. Epub 2016 Mar 2.
Translational Genomics and Targeted Therapeutics in Solid Tumours Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain. Electronic address:


Corrigendum re: "TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer" [Eur Urol 2016;70:709-13].
Eur Urol 2017 08 1;72(2):e49. Epub 2017 Mar 1.
Translational Genomics and Targeted Therapeutics in Solid Tumours Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain. Electronic address:

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Stem Cell Reports 2017 05 27;8(5):1392-1407. Epub 2017 Apr 27.
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199 - 203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. Electronic address:


OF